Skip to main content
. 1998 Apr 14;95(8):4630–4634. doi: 10.1073/pnas.95.8.4630

Figure 4.

Figure 4

ALT-711 decreases IgG crosslinked to the RBC surface. (Upper) Chronic treatment decreases RBC-IgG already after 1 week of chronic dosing. Values are means ± SD of the percent change with respect to day 0. All time points P < 0.01 vs. predose and vs. vehicle. (Lower) RBC-IgG levels decrease dose-dependently after 8 days of oral dosing with ALT-711. Diabetic rats were treated for 8 days with ALT-711 in doses varying from 0.01 to 10 mg/kg. All doses in the range 0.03–10.0 are P < 0.01 vs. predose values.